Key Releases are ad hoc announcements pursuant to SIX Swiss Exchange Article 53 Listing Rules.
News archive
News Archive Navigation
News Archive Navigation Language
November 2021
-
Featured NewsNovartis at ASH
Latest resources and news surrounding Novartis data featured at the 63nd American Society of Hematology Annual Meeting (ASH).
-
The art of drug design in a technological age
Novartis is collaborating with Microsoft to apply machine learning to medicinal chemistry — part of an effort to leverage AI to bring treatments to patients more efficiently.
-
Stopping this coronavirus – and the next one
Inside the hunt for new antivirals to combat the current pandemic and to prepare for future ones.
-
Media ReleaseNovartis presents positive Phase III results for Cosentyx® in children with active enthesitis-related arthritis (ERA) and juvenile psoriatic arthritis (JPsA) at ACR 2021Treatment with Cosentyx® (secukinumab) resulted in a 72% reduced flare risk versus placebo, with improvement in disease activity over two years across both enthesitis-related arthritis (ERA) and…
-
Media ReleaseNovartis announces new publication in Cephalalgia of data showcasing superior tolerability and efficacy of Aimovig® (erenumab) compared with topiramate in migraine preventionHER-MES, a Phase IV study, is the first and only randomized, double blind, head-to-head study that compares an antibody targeting the CGRP pathway, Aimovig® (erenumab), with an oral prophylactic…
-
Media ReleaseLeqvio®* (inclisiran) reduced LDL-C in people who are overweight or obeseRegardless of body mass index (BMI), Leqvio provided sustained and effective LDL-C reduction of ~50% with two doses a year**, according to pooled analysis of three Phase III studies 1Being overweight…
-
Solving the puzzle of immunotherapy
From an eccentric idea to a revolution in medicine – the history of immunotherapy and a peek into its future.
-
Media ReleaseNovartis iptacopan meets primary endpoints in Phase II study in rare kidney disease C3 glomerulopathy (C3G)Statistically significant and clinically important reductions in proteinuria were achieved for the primary endpoint for patients with C3G1 Additionally, statistically significant reduction in C3…
-
Media ReleaseNew data at ASH spotlight Novartis recently approved Scemblix®, next-generation CAR-T platform and expanding hematology portfolioNew longer-term efficacy and safety data from pivotal Phase III ASCEMBL study for recently US-approved Scemblix® (asciminib) in patients with PH+ CML-CPEarly findings from YTB323 and PHE885 CAR-T…
-
Featured NewsRaising awareness of prostate cancer during Movember
Despite advancements in care, prostate cancer is one of the most frequently diagnosed cancers around the world. This Movember, we’re focused on raising awareness of prostate cancer.
-
Breaking down barriers for patients with sickle cell disease
One patient’s story reveals the hidden obstacles to better health – and opportunities to help clear them.
Pagination
- ‹ Previous page
- 1
- …
- 25
- 26
- 27
- 28
- 29
- 30
- 31
- …
- 152
- › Next page